This post was originally published on this site
The move was the first announcement by newly appointed CEO Roy Jakobs, who took over the reins earlier this month as the company continued to grapple with the fallout of its costly recall of respiratory machines and with ongoing supply chain problems that led to a profit warning last month.
“My immediate priority is to improve execution so that we can start rebuilding the trust of patients, consumers and customers,” Jakobs said in a statement.
“This includes the difficult, but necessary decision to immediately reduce our workforce by around 4,000 roles globally, which we do not take lightly.”
The cuts represents just over 5% of the company’s workforce based on last year’s total of 78,000.
The company said it expected the reorganisation to cost around 300 million euros ($295.41 million) in the coming quarters.
($1 = 1.0155 euros)
